Abbott Laboratories (ABT) Non-Current Deferred Tax Liability (2010 - 2021)

Abbott Laboratories (ABT) has 12 years of Non-Current Deferred Tax Liability data on file, last reported at $1.4 billion in Q4 2021.

• For the quarter ending Q4 2021, Non-Current Deferred Tax Liability fell 1.0% year-over-year to $1.4 billion; the trailing twelve-month figure through Dec 2021 stood at $1.4 billion (down 1.0% YoY), and the FY2021 full-year result was $1.4 billion, down 1.0% from the prior year.
• Non-Current Deferred Tax Liability eased to $1.4 billion in Q4 2021, from $1.4 billion in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $2.1 billion in Q4 2018 to a low of $1.4 billion in Q4 2021.
• A 5-year average of $1.7 billion and a median of $1.5 billion in 2019 frame the typical range for Non-Current Deferred Tax Liability.
• Across the five-year window, Non-Current Deferred Tax Liability surged 463.48% in 2017 and retreated 24.81% in 2019, its largest moves.
• Tracing ABT's Non-Current Deferred Tax Liability over 5 years: stood at $2.0 billion in 2017, then grew by 2.49% to $2.1 billion in 2018, then dropped by 24.81% to $1.5 billion in 2019, then retreated by 9.06% to $1.4 billion in 2020, then decreased by 1.0% to $1.4 billion in 2021.
• Business Quant data shows ABT's Non-Current Deferred Tax Liability at $1.4 billion in Q4 2021, $1.4 billion in Q4 2020, and $1.5 billion in Q4 2019.